Erste Group downgraded AbbVie (ABBV) to Hold from Buy. The company recently announced a significant guidance reduction due to a required write-off of research and development costs, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $240 from $205 at Citi
- AbbVie announces FDA approval of updated indication statement for RINVOQ
- AbbVie to present new data from ADC platform at ESMO
- AbbVie price target raised to $284 from $231 at Piper Sandler
- Needham medtech & diagnostics analysts hold analyst/industry conference call